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Abstract
Tributyltin (TBT) is found in human blood and other tissues and thus is of considerable concern as 
to its effects on human health. Previous studies have demonstrated that TBT has detrimental 
effects on immune function. Recently, we found that exposures to TBT caused increased secretion 
of two important pro-inflammatory cytokines, tumor necrosis factor alpha (TNFα) and interferon 
gamma (IFNγ). Elevation of either of these cytokines has the potential to cause chronic 
inflammation, which is an important factor in a number of diseases including cancer. The current 
study examined the mechanism of TBT-induced elevations of TNFα and IFNγ secretion and 
found that the p38 MAPK pathway was essential to the ability of TBT to stimulate secretion. 
Additionally, this study demonstrated that increased secretion of these cytokines was due to TBT-
induced increases in their overall synthesis, rather than simply being due to an increase in the 
release of already formed proteins. The TBT-induced increases in synthesis were evident within 6 
h of exposure. The p38 MAPK pathway is also necessary for the TBT-induced increases in both 
TNFα and IFNγ synthesis. The role of increased transcription of TNFα and IFNγ mRNA in 
response to TBT exposures as a possible explanation for the increased synthesis of these cytokines 
was also examined. It was found that increased mRNA levels did not appear to fully explain the 
increases in either TNFα or IFNγ synthesis. Thus, TBT is able to increase secretion of two 
important pro-inflammatory cytokines by increasing their synthesis.
INTRODUCTION
Tributyltin (TBT) has been used as an ingredient in antifouling paints as well as an 
antifungal agent and biocide in textiles, paper production, industrial cooling waters and 
wood preservation (Kimbrough, 1976; Laughlin and Linden, 1985; Roper, 1992). Although 
TBT uses have been banned or severely restricted in many parts of the world, due to its 
persistent properties, residues of TBT are still found in the environment and cause harmful 
health effects in wildlife and humans (Gipperth, 2009; Loganathan et al., 2000; Loganathan, 
2016, Kirchner et al., 2010; Gao et al. 2017). Human exposures to TBT are thought to 
mainly arise from the intake of contaminated food (WHO, 1990; Kannan et al., 1995). Blood 
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levels of TBT range as high as 261 nM (85 ng/mL) (Whalen et al., 1999; Kannan et al., 
1999). Other sources for dermal or pulmonary exposures include, disinfectants in specific 
wax, polish and cleansing products, catalysts and pesticides (Kannan et al., 1999; Takahashi 
et al., 1999). The exposure of mammals to TBT has been shown to cause increased 
incidences of tumors (Wester et al., 1990), decreased NK cell function (Ghoneum et al., 
1990), thymic atrophy and thymus dependent immunosuppression (Snoeij et al., 1987, 1989; 
Vos et al. 1990). TBT has also been detected in organs such as the heart, liver, kidney and 
stomach (Gui-Bin et al., 2000). TBT decreases lytic function, target-binding function, cell-
surface protein expression and cytolytic protein expression in human natural killer (NK) 
cells at levels that are in the range found in human blood (Whalen et al., 1999; Dudimah et 
al., 2007; Whalen et al., 2002; Thomas et al., 2004).
Recent studies have shown that exposure to TBT alters the secretion of several pro-
inflammatory cytokines including, interleukin 1 beta (IL-1β), interferon gamma (IFNγ), 
tumor necrosis factor alpha (TNFα), and IL-6 from human immune cells (Hurt et al. 2013; 
Lawrence et al., 2015; Brown and Whalen, 2015; Brown et al., 2017).
IFNγ is produced by T cells, NK cells, and to a more limited extent by myeloid lineage cells 
such as monocytes and macrophages (Billiau and Matthys, 2009; Darwich et al., 2008; 
Andoniou et al., 2008; Girart et al., 2007). TNFα is made by various cell types including, 
lymphocytes, monocytes, macrophages, smooth muscle cells, fibroblasts, endothelial cells, 
epithelial cells, adipocytes and osteoblasts with activated macrophages and T lymphocytes 
being the predominant producers of TNFα (Locksley, 2001). Elevated levels of both IFNγ 
and TNFα are associated with chronic inflammation which has been linked to the 
development of a number of diseases including cancer (Macarthur et al., 2004; Balkwill and 
Mantovani, 2001). Elevated levels of IFN have been shown to facilitate the development of 
gastrointestinal cancers (Macarthur et al., 2004) and elevated TNFα may alter the 
proliferation and invasiveness of tumor cells, due to its capacity to act as a growth factor, 
angiogenic factor and inducer of epithelial-mesenchymal transition (Vajdic and van 
Leeuven, 2009). The secretion and synthesis of both IFNγ and TNFα are regulated by 
mitogen activated protein kinases (MAPKs) (Schoenborn and Wilson, 2007; Gaestel et al., 
2009) and by nuclear factor kappa B (NFκB) (Strengell et al., 2003; Gaestel et al., 2009). 
Additionally, TNFα converting enzyme, TACE, is needed for the secretion of the soluble 
form of TNFα (Goetz et al., 2004).
Tight regulation of levels of both IFNγ and TNFα are necessary to prevent loss of immune 
competency (too little) or chronic inflammation (too much). As mentioned above, TBT has 
been shown to dysregulate the secretion of both TNFα and IFNγ from immune cells (Hurt 
et al. 2013; Lawrence et al., 2015).
In the current study, we examine the signaling pathways that may regulate the previously 
described TBT-induced increases in secretion of these two important pro-inflammatory 
cytokines (Hurt et al. 2013; Lawrence et al., 2015). Additionally, studies are carried out to 
determine whether TBT-induced alterations in the synthesis of IFNγ and/or TNFα are 
occurring. It is possible that TBT only alters the secretory pathway of already existing 
cytokines, without affecting de novo synthesis of these proteins. Finally, IFNγ and TNFα 
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mRNA levels are examined to determine if there are TBT-induced changes in the levels of 
these transcripts that are responsible for any alterations in protein synthesis.
MATERIALS AND METHODS
Preparation of monocyte- depleted PBMCs
PBMCs were isolated from Leukocyte filters (PALL- RC2D) obtained from the Red Cross 
Blood Bank Facility (Nashville, TN) as described in Meyer et al., 2005. Leukocytes were 
retrieved from the filters by back-flushing them with elution medium (PBS containing 5 mM 
disodium EDTA and 2.5% [w/v] sucrose) and collecting the eluent. Eluent was layered onto 
Ficoll-Hypaque (1.077g/mL) and centrifuged at 1200 g for 30 min. PBMCs were collected 
and washed (250 g, 10 min) with PBS. Cells were then suspended in complete medium 
which consisted of RPMI-1640 supplemented with 10% heat-inactivated BCS, 2 mM L-
glutamine and 50 U penicillin G with 50 μg streptomycin/mL. Monocyte-depleted PBMCs 
(10–20% CD16+, 10–20 % CD56+, 70–80% CD3+, 3–5% CD19+, 2–20% CD14+) were 
prepared by incubating the cells in glass Petri dishes (150 × 15 mm) at 37 °C and 
air/CO2, 19:1 for a total of 1.5 h.
Chemical preparation
TBT was purchased from Sigma-Aldrich (St. Louis, MO). TBT was a neat standard, 
dissolved initially in deionized water to give a 1 mM solution. Desired concentrations of 
TBT were prepared by dilution of the stock into complete media.
Cell treatments
MD-PBMCs were treated with TBT with appropriate control at concentrations of 2.5–200 
nM for 10 min, 30 min, 6 h, and 24 h. Following the incubations, the cells were pelleted and 
the supernatants were collected and frozen at -70°C until assay. Cell pellets were lysed and 
stored at −70°C for western blot analysis.
Inhibitor Preparation
Enzyme inhibitors were purchased from Fischer Scientific (Pittsburgh, PA). The stock 
solution for each inhibitor was a 50 mM solution in dimethylsulfoxide (DMSO). JNK 
Inhibitor (BI78D3), MEK1/2 pathway inhibitor (PD98059), p38 inhibitor (SB202190), 
NFκB inhibitor (BAY11-7085) and TACE inhibitor (Batimastat) were prepared by dilution 
of the stock solution into cell culture media.
Cell treatments with Inhibitors
For pathway inhibitor experiments, MD-PBMCs were treated with pathway inhibitors 1h 
before adding TBT at concentrations of 5, 10, 25 nM TBT for 24 h. Following the 
incubations, the cells were pelleted and supernatants were collected and stored at −70 °C 
until assaying for IFNγ and TNFα.
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Cell viability was assessed at the beginning and end of each exposure period. Viability was 
determined using the trypan blue exclusion method. Cells were mixed with trypan blue and 
counted using a hemocytometer. The total number of cells and the total number of live cells 
were determined for both control and treated cells to determine the percent viable cells. 
Viability was not significantly affected with any of the treatments.
IFNγ and TNFα secretion assay
IFNγ and TNFα levels were assessed using the OptEIA™ enzyme-linked immunosorbent 
assay (ELISA) human IFNγ and TNFα kits (BD-Pharmingen, San Diego, CA) respectively. 
Briefly, appropriate capture antibody was applied to the wells of a 96 well flat-bottom 
microwell plate specifically designed for ELISA (Fisher, St. Louis MO) after removal of 
excess capture antibody (by washing with PBS containing 0.05% Tween-20), the wells were 
treated with blocking buffer. Blocking buffer was removed and cell supernatants and IFNγ 
or TNFα standards were added to the plate. Following the incubation with samples and 
standards, detection antibody was added. Following the removal of the detection antibody, a 
substrate solution was added to each well. Incubation with substrate was ended by addition 
of acid and the absorbance measured at 450 nm on a Thermo Labsystems Multiskan 
MCC/340 plate reader (Fisher Scientific).
Gel Electrophoresis and Western Blotting
MD-PBMCs at a concentration of 4 million/0.67mL were exposed to TBT for 10 min, 30 
min, 6 h or 24 h. Following the treatments, the cells were centrifuged and the cell pellets 
lysed using 133μL of lysis buffer (Active motif, Carlsbad, CA) 4 million cells. Cell lysates 
were then stored frozen at −80 °C until they were run on 10% SDS-PAGE (sodium 
dodecylsulfate polyacrylamide gel electrophoresis). Control and treated cells for a given 
experimental setup were from an individual donor. The PVDF membrane was 
immunoblotted with anti-IFNγ, anti-TNFα and anti- β-actin antibodies (Cell signaling 
Technologies, Beverly, MA). Antibodies were then visualized using an ECL 
chemiluminescent detection system (Amersham, Piscataway, NJ) and UVP Software. The 
density of each protein band was determined by densitometric analysis using the UVP 
analysis software. The settings on the image station were optimized to detect the largest 
possible signal range and prevent saturation of the system. Differences in protein expression 
were determined relative to an internal control. This determination provided comparative 
quantitation by evaluating whether a given treatment changed the expression of IFNγ and 
TNFα relative to untreated cells. β-actin levels were determined for each condition to verify 
that equal amounts of protein were loaded. Additionally, the density of each protein band 
was normalized to β- actin to correct for any minor differences in the loading among the 
lanes.
RNA Isolation and RT-qPCR
RNA from MD-PBMCs was extracted with RNeasy Mini kit (Qiagen). RNA concentrations 
were measured with a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, 
DE). PCR primers were designed using Primer Express 2.0 (Applied Biosystems):
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IFNγ forward sequence TGC AAT CTG AGC CAG TGC TT
IFNγ reverse sequence CAG GGT CAC CTG ACA CAT TCA A
TNFα forward sequence TCC CCT GCC CCA ATC C
TNFα reverse sequence CCA ATT CTC TTT TTG AGC CAG AA
All RT-qPCR assays were conducted using QuantiTect SYBR Green RT-PCR kit (Qiagen). 
Reaction was done in 20 μL containing 50 ng of total RNA and 0.4 μM of each primer. 
Thermal cycles contained one cycle of pre-incubation at 50 °C for 10 minutes and 95 °C for 
15 minutes, 35 cycles of amplification (95 °C for 15 seconds and 60 °C for 60 seconds). 
Primers were validated by melting curve analysis, standard curve and non-template control 
reactions. Each concentration was analyzed in duplication with RT- qPCR to determine 
amplification efficiency.
Statistical Analysis
Statistical analysis of the data was performed by using ANOVA and Student’s t test. Data 
were initially compared within a given experimental setup by ANOVA. A significant 
ANOVA was followed by pair wise analysis of control versus exposed data using Student’s t 
test, a p value of less than 0.05 was considered significant.
RESULTS
Effects of TBT Exposures on IFNγ Secretion from MD-PBMCS Treated with Selective 
Enzyme Inhibitors
NFκB inhibitor (BAY 11-7085)—MD-PBMCs were exposed to the NFκB inhibitor (BAY 
11-7085) for 1 h, before a 24 h TBT exposure to 50, 25 and 10 nM TBT. These 
concentrations of TBT were examined as one or more had produced significant elevations in 
IFNγ secretion in previous studies (Lawrence et al., 2015). Cells from 4 different donors all 
showed increased secretion of IFNγ after exposures to 50, 25, or 10 nM TBT. When the 
NFκB pathway was inhibited, all donors showed somewhat diminished TBT-induced IFNγ 
secretion. For instance, cells from donor F380 showed increases of 2.9, 3,8 and 5.2 fold with 
exposures to 10, 25 and 50 nM TBT. When the inhibitor was present, these same 
concentrations of TBT showed diminished effects on IFNγ secretion of 1.6, 3.0 and 3.7 fold 
(Figure 1A). Results were replicated in cells prepared from 3 additional donors. These 
results indicate that the NFκB pathway is needed to a limited extent for TBT-induced 
secretion of IFNγ.
JNK inhibitor (B178D3)—When the JNK pathway was inhibited by a 1 h pre-treatment 
with JNK inhibitor (B178D3), the ability of TBT to stimulate increased secretion of IFNγ 
from lymphocytes was unchanged. This effect was seen in MD-PBMCs from 4 individual 
donors. The resultsindicated that TBT-induced secretion of IFNγ was not dependent on 
activation of the JNK pathway (data not shown). Thus the JNK pathway cannot be seen as 
essential to TBT-induced increases in IFNγ.
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Mitogen activated protein kinase kinase (MAP2K)/ MEK Inhibitor (PD98059)—
When the ERK1/2 pathway was inhibited prior to exposing cells to TBT, there was no 
consistent effect on TBT-induced increases in IFNγ (data not shown). These results suggest 
that TBT does not require the ERK1/2 pathway to induce increase in IFNγ secretion.
p38 Inhibitor (SB202190)—Blocking the p38 pathway decreased the ability of TBT to 
induce elevations of IFNγ in cells from 4 separate donors. Results indicated that the p38 
pathway is needed for TBT to elevate IFNγ. For instance, cells from donor F380 showed 
increases of 2.4, 2.4 and 1.5 fold with exposures to 10, 25, and 50 nM TBT. After inhibition 
of the p38 pathway, these same concentrations showed a dramatic reduction in TBT-induced 
IFNγ secretion (Figure 1B). Similar results were seen in all donors tested. These data 
suggest that TBT heavily relies on the p38 pathway to promote increases in IFNγ secretion.
Effects of TBT exposures on cellular synthesis of IFNγ (secretion + intracellular levels)
10 min exposure to TBT—Both secreted and intracellular levels of IFNγ were measured 
in cells from the same donor. After exposure to TBT (0–200 nM) the supernatants were 
collected for measuring secreted IFNγ and the cells were lysed to measure intracellular 
levels. Synthesis of IFNγ is measured as the combined effect on intracellular levels and 
secreted levels. Cells from a total of 4 individual donors were examined for the effects of 
TBT on IFNγ secretion. There was no consistent effect of TBT exposures on IFNγ 
production seen after 10 minutes (data not shown).
30 min exposure to TBT—The synthesis of IFNγ in MD-PBMCs exposed to 0–200 nM 
TBT for 30 minutes were analyzed from 4 separate donors (data not shown). Again, there 
was no consistent effect of TBT exposures on the synthesis of IFNγ after 30 min of 
exposure.
6 h exposure to TBT—Synthesis (intracellular + secreted levels) of IFNγ after exposure 
to TBT for 6 h was increased at 1or more concentration of TBT in cells from each of the 4 
donors that were examined (Figure 2A). For instance, cells from donor F234 showed 
increased synthesis (secreted+intracellular levels) of IFNγ at each TBT exposure. The 
increases ranged from 1.1 fold at the 200 nM TBT concentration to 2.3 fold at the 2.5 nM 
exposure. The extent of the increases in synthesis and the concentrations at which they 
occurred varied among the donors. The fold increase compared to control for cells from 3 
other donors are summarized in the bar chart of Figure 2A (control level =1). The results 
indicate that TBT-induced increases in IFNγ are detectable within 6 h of exposure to TBT.
24 h exposure to TBT—The results of 24 h exposure of MD-PBMCs to 200–2.5nM TBT 
on the synthesis of IFNγ from 4 donors are shown in Figure 2B. After 24h of exposure to 
TBT, cells from all donors demonstrated increased synthesis of IFNγ at a minimum of 4 
concentrations. For example, cells from donor F200 showed significant increases in 
synthesis at 200, 100, 50, 25, 10 and 2.5 nM TBT. Fold increases in synthesis for cells from 
donor F200 (fold increases in intracellular and secreted levels combined) at each of these 
concentrations were 25, 5.6, 3.3, 2.5, 2.8, and 1.5, respectively. The fold increases in 
synthesis of IFNγ stimulated by TBT in cells from the other donors are shown in the bar 
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chart of Figure 2B. These data indicate that very substantial changes in IFNγ synthesis 
occur after an incubation of 24 h with TBT.
Effect of p38 pathway inhibitor (SB202190) on TBT-induced increases in IFNγ synthesis
As p38 was shown to be essential for TBT-induced increases in IFNγ secretion, the effects 
of the p38 inhibitor, SB202190, were examined on TBT-induced increases in IFNγ 
synthesis. Results from pre-treating MD-PBMCs with SB202190 for 1 h prior to exposing to 
10, 25, and 50 nM TBT for 24 h are shown in Figure 2C (representative experiment). Cells 
from donor F443 showed TBT-induced increases in TNFα synthesis of 1.8 at 50 nM and 1.9 
at 25 nM and these were decreased to 1.2 (50 nM) and no increase (25 nM) when the p38 
pathway was inhibited. Similar results were seen in cells from 3 additional donors (data not 
shown). These data indicate that like TBT-induced increases in IFNγ secretion, TBT 
requires the p38 MAPK pathway to induce increases in IFNγ production.
Effects of 6 h and 24 h exposures to TBT on IFNγ mRNA levels in MD-PBMCs
RT-qPCR was carried out to examine whether TBT-induced changes in IFNγ synthesis were 
due to changes in the levels of mRNA. MD-PBMCs from 4 donors were exposed to 0–200 
nM TBT for 6 h and 24 h (Table 1). mRNA levels were increased in cells from 1 of 4 donors 
tested after 6 h of incubation and in cells from 2 of 4 donors after 24 h of incubation. 
Increased mRNA was seen in cells from half of the donors tested by 24 h. Thus, it appears 
that TBT may at least in some instances be increasing synthesis of IFNγ by increasing in 
IFNγ mRNA.
Effects of TBT Exposures on TNFα Secretion from MD- PBMCS Treated with Selective 
Enzyme Inhibitors
A previous study from our lab showed that TNFα secretion was elevated by exposures to 10, 
25, and 50 nM TBT (Hurt et al., 2013). Here the mechanism by which TBT induces 
elevations in TNFα secretion was investigated using inhibitors of signaling pathways, 
known to be utilized in the production of TNFα as described in the introduction.
NFκB Inhibitor (BAY 11–7085)—When the NFκB pathway was inhibited, there was no 
consistent change in the TBT-induced increases in TNFα secretion (data not shown). These 
results indicated that the NFκB pathway is not essential for TBT-induced secretion of 
TNFα.
JNK Inhibitor (BI78D3)—MD-PBMCs pre-treated with the JNK pathway inhibitor 
(B178D3) still exhibited TBT-induced increases in TNFα when exposed to 50, 25, and 10 
μM TBT (data not shown). These results suggest that the JNK pathway is not needed for 
TBT-induced increases in TNFα secretion.
Mitogen activated protein kinase kinase (MAP2K)/ MEK Inhibitor (PD98059)—
After inhibition of the ERK1/2 pathway, TBT was able to induce increased secretion of 
TNFα from cells from all donors examined (data not shown). This indicates that TBT is not 
utilizing this pathway to stimulate TNFα secretion.
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p38 Inhibitor (SB202190)—Inhibiting the p38 pathway with SB202190 decreased TBT-
induced increases in TNFα secretion in cells prepared from 4 different donors. These data 
indicated that the p38 pathway is needed for TBT to elevate TNFα. Cells from a 
representative donor (F370) showed increases of 1.5, 1.8 and 2.1 fold with exposures to 10, 
25, and 50 nM TBT (Figure 3A). After inhibition of the p38 pathway, these same 
concentrations showed no TBT-induced increase in TNFα secretion. Results were replicated 
in cells prepared from 3 additional donors (data not shown).
TACE Inhibitor—Inhibiting TACE with batimastat also decreased the ability of TBT to 
induce increases in TNFα secretion. When TACE was inhibited cells from all donors 
showed a diminished response to at least one concentration of TBT. Cells from 4 distinct 
donors were examined. For instance, cells from donor F274 (Figure 3B) showed increases of 
1.5, 3.4 and 5.8 fold following exposures to 10, 25, and 50 nM TBT. After inhibition of 
TACE, 10 nM TBT caused no increase in TNFα secretion while 25 and 50 nM TBT 
produced diminished increases of 2.2 and 3.4 fold, respectively. Similar results were seen in 
cells from 3 other donors (data not shown). These data indicate that TBT requires the 
activation of TACE to cause increases in TNFα secretion. This reflects the essential role of 
TACE in the secretion of TNFα.
Effects of TBT exposures on cellular synthesis of TNFα (secretion + intracellular levels)
10 min exposure to TBT—MD-PBMCs exposed to 200–2.5nM TBT for 10 min showed 
no consistent increases in synthesis of TNFα. Cells from 4 donors were examined (data not 
shown).
30 min exposure to TBT—As was seen after 10 min, there is no consistent effect of TBT 
exposures on TNFα synthesis after 30 min, in cells prepared from 4 separate donors (data 
not shown)
6 h exposure to TBT—Effects of TBT on the synthesis of TNFα are shown in Figure 4A. 
All donors showed increased TNFα synthesis at 2 or more TBT exposures. Cells from donor 
F250 showed increased synthesis (secreted+intracellular levels) of TNFα compared to 
control cells at 3 TBT exposures. (Figure 4A). The fold increase compared to control for 3 
other donors are summarized in the bar chart of Figure 4A. These data indicate that 
increases in TNFα synthesis induced by TBT-exposures are seen in cells from all donors 
within 6 h of exposure.
24 h exposure to TBT
After 24 h of exposure to TBT, cells from all donors showed increased TNFα synthesis at 
every concentration of TBT examined (Figure 4B). Thus, while the increased production of 
TNFα appears consistently after 6 h exposure, it becomes much greater and is seen at many 
more TBT-exposure levels after 24 h. For example, cells from donor F200 showed 
significant increases in synthesis (either secretion and/or intracellular levels) at 200, 100, 50, 
25, 10, 5, and 2.5 nM TBT. Fold increases in synthesis for cells from F200 (fold increases in 
intracellular and secreted levels combined), at each of these concentrations were 13.4, 4.9, 
3.1, 2.4, 2.2, 1.3, and 2.3, respectively. All other donors showed similar trends for increased 
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synthesis of TNFα after 24 h. The fold increase compared to control for the other donors are 
summarized in the bar chart of Figure 4B.
Effect of p38 pathway inhibitor (SB202190) on TBT-induced increases in TNFα synthesis
p38 Inhibitor (SB202190)—Results from pre-treating MD-PBMCs with SB202190 for 1 
h prior to exposing to 10, 25, and 50 nM TBT for 24 h are shown Figure 4C (representative 
experiment). Cells from all donors showed increased TNFα synthesis in response to TBT 
and these increases were diminished when the p38 MAPK pathway was inhibited. The cells 
from donor F433 (Figure 4C) showed TBT-stimulated fold increases in TNFα synthesis of 
1.45 at 50 nM and 1.74 at 25 nM and these were completely blocked in the presence of 
SB202190. Similar results were seen in cells from three additional donors. These data 
indicate that the increased production of TNFα that occurs in response to TBT exposures 
requires the p38 pathway.
Effects of 6 h and 24 h exposures to TBT on TNFα mRNA levels in MD-PBMCs
RT-qPCR was used to examine whether TBT-induced changes in TNFα synthesis were due 
to changes in the levels of mRNA. MD-PBMCs from 4 donors were exposed to 0–200 nM 
TBT for 6 h or 24 h. The results are shown in Table 2. mRNA levels were increased in cells 
from 2 of 4 donors tested after 6 h of incubation and in cells from 1 of 4 donors after 24 h of 
incubation. Increased mRNA was seen in cells from half of the donors tested by 6 h. Thus, it 
appears that, as with IFNγ, TBT may in some instances be increasing synthesis of TNFα by 
increasing in TNFα mRNA.
DISCUSSION
IFNγ and TNFα are important regulators of immune responsiveness that are produced 
primarily by T and NK lymphocytes and to some extent by myeloid cells (Zaidi and 
Merlino, 2011, Billiau and Matthys, 2009; Darwich et al., 2008; Goetz et al., 2004). It is 
important to determine the effects of environmental contaminants such as the TBT (which 
has been found in human blood) (Whalen et al., 1999; Kannan et al., 1999) on the secretion 
of these potent regulators. TBT-induced alterations of both IFNγ and TNFα have been 
observed in vivo (Lawrence et al., 2016). Both cytokines are potent pro-inflammatory 
stimuli and as such have the capacity to cause chronic inflammation. Chronic inflammation 
has been shown to be associated with a number of disease states including certain cancers 
such as gastrointestinal cancers (Macarthur et al., 2004; Grivennikov and Karin, 2011). 
Previous studies demonstrated that exposure to TBT at some levels increased the secretion 
of both TNFα and IFNγ (Hurt et al., 2013; Lawrence et al., 2015). The current study 
investigated the mechanism of the TBT-induced increases in secretion of both TNFα and 
IFNγ that were noted in these past studies. This study also addressed whether these TBT-
induced increases in TNFα and IFNγ were due simply to release of already existing 
cytokine, or if TBT was stimulating cellular synthesis of these two cytokines. The fact that 
levels of TBT that caused increased secretion of these two extremely potent inflammatory 
signals occur in humans makes examination of the mechanism of this elevation of critical 
importance.
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Previous studies have shown that TBT is able to activate MAPKs in NK cells (Aluoch and 
Whalen, 2005; Aluoch et al., 2006; Aluoch et al., 2007). The secretion and production of 
IFNγ is dependent on mitogen activated protein kinases (MAPKs) signaling (Schoenborn 
and Wilson, 2007) and in some cases, nuclear factor kappa B (NFκB) (Strengell et al., 
2003). TNFα is also regulated by MAPKs and NFκB (Gaestel et al., 2009) as well as TNFα 
converting enzyme (TACE, also known as ADAM-17) (Goetz et al., 2004). The current 
studies investigated the role of MAPKs and other signaling pathways, including NFκB and 
TACE, in TBT-induced increases in IFNγ and TNFα secretion. The results indicated that 
increased secretion of both IFNγ and TNFα in response to TBT was dependent on the p38 
MAPK pathway. The dependence of TBT-induced secretion of IFNγ and TNFα synthesis 
on p38 activation is consistent with the role of TBT as a cell stressor (Sabio and Davis, 
2014). TBT-induced secretion of TNFα was also dependent on TACE activity, but this is 
true of all TNFα secretion and was not indicative of the mechanism by which TBT was 
causing increased secretion of TNFα. It has previously been shown that the TBT-induced 
increases in IL-1β secretion is most significantly dependent on the ERK1/2 MAPK pathway 
(Brown and Whalen, 2015), in contrast to what was seen with IFNγ and TNFα.
While it was clear that TBT could alter secretion of IFNγ and TNFα, it was not clear if this 
was due to increased intracellular synthesis of the cytokines or if it was stimulating the 
release of pre-existing IFNγ and TNFα. The studies presented here indicate that TBT 
induced small, but consistent, increases in the overall production of both IFNγ and TNFα 
within 6 hours of exposure to the contaminant and very substantial increases after 24 h. 
Thus, TBT is causing cells to secrete increased amounts of IFNγ and TNFα, due to its 
ability to increase the cellular synthesis of each of these cytokines and not simply by 
triggering the release of already synthesized cytokine. Additionally, we examined whether 
the p38 MAPK pathway was necessary for the TBT-stimulated increases in IFNγ and TNFα 
protein synthesis. The data indicated that the p38 pathway was responsible for the increased 
production of each of these cytokines in response to TBT. This is an important finding, in 
that it suggests that increased cellular synthesis of these two extremely potent inflammatory 
proteins is occurring in response to exposure to a ubiquitous environmental contaminant in a 
p38 dependent manner. Thus, TBT may have the capacity to contribute to a state of chronic 
inflammation which could lead to increased risk of cancer, certain autoimmune diseases and 
heart failure (Macarthur et al., 2004; Grivennikov and Karin, 2011; Chowers and Allez, 
2010; Shirazi et al., 2017).
Once it was established that TBT was causing an increase in immune cell synthesis of IFNγ 
and TNFα, it was of interest to examine if this was primarily due to an effect of TBT on the 
mRNA levels of either or both of these cytokines. It was found that while TBT caused an 
increase in the levels of both IFNγ and TNFα proteins, increases in the levels of mRNA for 
either cytokine were not consistent. This indicates that while TBT utilizes the p38 MAPK 
pathway to elevate the levels of both IFNγ and TNFα in immune cells, it may not 
necessarily be achieving elevation of these proteins via an increase in the levels of their 
respective mRNAs. Translational regulation of both IFNγ and TNFα has been described 
(Mazumder et al., 2010). For instance, TNFα has an AU-rich region (element) (ARE) in the 
3’ untranslated region (UTR) of its transcript. A protein designated heterogeneous nuclear 
ribonucleoprotein-A1 (hnRNP-A1) binds to the ARE in the TNFα transcript and blocks 
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translation. This inhibition of TNFα translation can be reversed by a p38 MAPK pathway-
dependent phosphorylation of hnRNP-A1 which reduces its ability to bind to the ARE 
(Buxadé et al., 2005). Future studies will examine whether TBT may have effects on the 
translational process thus, leading to elevations of these protein levels by that route.
In summary, the current study addresses the mechanism by which TBT leads to increased 
secretion of both IFNγ and TNFα. The results showed that TBT appeared to predominantly 
be utilizing the p38 MAPK pathway to cause increased secretion of both cytokines. The 
question of whether TBT only induced increased secretion of already existing cytokine or 
whether it induced synthesis of IFNγ and TNFα was also addressed. The data showed that 
TBT was able to induce increased synthesis of both cytokines within 6 h of exposure at 
concentrations of TBT that have been found in human blood samples. The increased protein 
synthesis appears to be dependent on the p38 MAPK pathway but appears to be somewhat 
independent of increases in the mRNA for either IFNγ or TNFα.
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Effects of pathway inhibitors on secretion of IFNγ from MD-PBMCs exposed to TBT for 24 
h. A) Cells were exposed to the NFκB inhibitor (BAY 11–7085) or control for 1 h prior to 
being exposed to 0, 10, 25, and 50 nM TBT. Results are from a representative experiment 
(donor F380). These results were reproduced in cells from 3 additional donors. B) Cells 
were exposed to the p38 inhibitor (SB202190) or control for 1 h prior to being exposed to 0, 
10, 25, and 50 nM TBT. Results are from a representative experiment (donor F380). These 
results were reproduced in cells from 3 additional donors.
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Effects of varying lengths of exposure to TBT on IFNγ synthesis (secretion + intracellular 
level) from human MD-PBMCs. A) 6 h exposure to 0–200 nM TBT. The blot with 
accompanying secretion data is shown for the cells from donor F234. The changes in 
synthesis (fold increases in secretion+intracellular levels) for cells from 3 other donors are 
summarized in the bar chart. B) 24 h exposure to 0–200 nM TBT. The blot (with 
accompanying secretion changes) is shown for cells from donor F200 and the bar chart 
summarizes the data for 3 other donors. C) 24 h exposure to 0, 10, 25, 50 nM TBT +/− p38 
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pathway inhibitor. The blot (with accompanying secretion changes) is shown for cells from 
donor F443. These results were reproduced in cells from 3 additional donors.
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Effects of pathway inhibitors on secretion of TNFα from MD-PBMCs exposed to TBT for 
24 h. A) Cells were exposed to the p38 inhibitor (SB202190) or control for 1 h prior to being 
exposed to 0, 10, 25, and 50 nM TBT. Results are from a representative experiment (donor 
F370). These results were reproduced in cells from 3 additional donors. B) Cells were 
exposed to the TACE inhibitor (Batimastat) or control for 1 h prior to being exposed to 0, 10, 
25, and 50 nM TBT. Results are from a representative experiment (donor F272). These 
results were reproduced in cells from 3 additional donors.
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Effects of varying lengths of exposure to TBT on TNFα synthesis (secretion + intracellular 
level) from human MD-PBMCs. A) 6 h exposure to 0–200 nM TBT. The blot with 
accompanying secretion data is shown for the cells from donor F250. The changes in 
synthesis (secretion+intracellular levels) for cells from 3 other donors are summarized in the 
bar chart. B) 24 h exposure to 0–200 nM TBT. The blot (with accompanying secretion 
changes) is shown for cells from donor F200 and the bar chart summarizes the data for 3 
other donors. C) 24 h exposure to 0, 10, 25, 50 nM TBT +/− p38 pathway inhibitor. The blot 
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(with accompanying secretion changes) is shown for cells from donor F443. These results 
were reproduced in cells from 3 additional donors.
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Table 1
Effects of 6 h and 24 h exposures to TBT on IFNγ mRNA levels in human MD-PBMCs
6 h Interferon gamma mRNA in Arbitrary Units (mean±S.D.)
[TBT]
nM
F546 F549 F550 F552
0 19.2±0.6 15.4±1.4 26.4±2.4 48.3±8.1
2.5 18.5±0.9 18.4±2.1 21.1±2.0* 23.4±2.4*
5 19.9±1.5 19.6±0.8+ 22.4±2.5 28.4±2.1*
10 15.9±0.2* 13.6±2.4 17.2±0.3* 23.6±2.5*
25 17.1±1.3 15.8±0.4 18.1±0.2* 21.8±5.1*
50 12.8±0.2* 13.4±1.6 16.0±1.0* 15.6±4.2*
100 13.6±0.9* 16.4±1.6 17.0±0.6* 25.0±2.6*
200 11.4±0.5* 17.9±1.5 19.0±1.3* 22.1±4.1*
24 h Interferon gamma mRNA in Arbitrary Units (mean±S.D.)
[TBT]
nM
F419 F420 F425 F426
0 36.5±9.1 64.2±1.0 10.1±2.8 24.2±2.9
2.5 66.2±20 64.5±9.3 83.0±35 75.1±19.7
5 33.6±5.5 88.7±18 53.6±9.9+ 86.7±0.4+
10 29.1±3.6 21.2±4.7* 30.0±2.8+ 48.8±11.4
25 24.5±5.1 95.5±33 21.1±6.9 28.8±4.0
50 43.9±2.8 104±48 34.9±8.7+ 8.3±4.5
100 30.6±8.7 55.1±1.8 36.0±7.8+ 20.2±2.7
200 18.5±4.6 23.2±1.0* 15.0±7.3 17.8±6.1
Values are mean±S.D. of triplicate determinations.
+
Indicates a significant increase and
*
indicates a significant decrease in mRNA compared to control cells, p<0.05
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Table 2
Effects of 6 h and 24 h exposures to TBT on TNFα mRNA levels in human MD-PBMCs
6 h Tumor necrosis factor alpha mRNA, arbitrary units (mean±S.D.)
[TBT]
nM
F546 F549 F550 F552
0 15.4±1.8 10.8±1.6 22.7±4.3 28.0±1.9
2.5 13.7±0.8 13.0±1.1 22.0±1.0 24.7±1.5
5 15.4±0.6 16.9±1.7+ 24.3±4.1 29±4.1
10 14.8±0.4 14.9±0.4 23.7±2.2 26.9±0.9
25 16.9±0.6 17.0±1.6+ 22.8±1.7 24.1±3.4
50 15.9±0.9 16.0±2.6 19.2±2.3 24.2±4.0
100 20.7±1.2+ 18.5±2.5+ 21.4±0.5 33.9±9.4
200 18.4±0.7+ 15.6±0.4 17.1±3.0 30.4±1.5
24 h Tumor necrosis factor alpha mRNA, arbitrary units (mean±S.D.)
[TBT]
nM
F419 F420 F425 F426
0 43.6±4.0 26.3±4.6 3.5±1.0 34.7±4.7
2.5 40.4±9.1 24.9±6.5 27.5±2.0+ 32.6±10.1
5 34.0±4.8 17.1±7.0 23.2±4.2+ 21.8±3.9
10 23.0±2.6* 13.5±6.2* 11.0±1.4+ 37.5±18.7
25 19.6±6.1* 15.8±6.8* 11.7±4.1 28.1±10.7
50 27.4±7.2 21.1±7.6 23.2±6.9+ 25.5±5.9
100 33.0±6.6 16.9±5.2 23.7±6.5+ 24.2±1.0
200 25.2±8.9 15.8±4.1* 15.0±5.0 26.2±5.9
Values are mean±S.D. of triplicate determinations.
+
indicates a significant increase and
*
indicates a significant decrease compared to appropriate control, p<0.05
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